Role of human liver microsomes in in vitro metabolism of metamizole

Abstract :

Metamizole or Novalgin® is a widely used well-tolerated analgesic drug that is however compromised by agranulocytosis as an adverse effect. Subsequent to nonenzymatic hydrolysis, the primary metabolic step is N-demethylation of 4-methylaminoantipyrine (4-MAA) to 4-aminoantipyrine (4-AA). The aim of the present study was to identify the human cytochrome P-450 enzyme (CYP) mediating this reaction. This study identified the relevant CYP using virus-expressed isolated human CYP, human liver microsomes and rat liver microsomes with chemical inhibition studies. The substrate of 4-methylaminantipyrine was employed at six different concentrations (25, 50, 100, 400, 800 and 1200 µmol per l) with varying concentrations of selective inhibitors of CYP1A2 (furafylline, fluvoxamine), CYP3A4 (ketoconazole), CYP2A6 (coumarin), CYP2D6 (quinidine), CYP2C19 (omeprazole, fluvoxamine, tranylcypromine), CYP2C9 (sulphaphenazole) and CYP1A1 (alpha-naphthoflavone). 4-MAA and 4-AA were analyzed by HPLC and enzyme kinetic parameters (Km and Vmax) were determined by regression (Sigma plot 9.0). The N-demethylation of 4-MAA by microsomes prepared from baculovirus expressing human CYP was pronounced with CYP2C19. Intrinsic clearance of the most active enzymes was 0.092, 0.027 and 0.026 for the CYP enzymes 2C19, 2D6 and 1A2, respectively. Metabolism by human liver microsomes was strongly inhibited by fluvoxamine, omeprazole and tranylcypromine (IC50 of 0.07, 0.07 and 0.18, respectively) but with coumarin, sulphaphenazole, ketoconazole, moclobemide, quinidine alpha-naphthoflavone and furafylline were 0.79, 1.20, 1.36, 1.44, 3.46, 4.68 and 8.41, respectively. The enzyme CYP2C19 apparently has an important role in N-demethylation of 4-methylaminoantipyrine which should be further analyzed in clinical studies and which may also be interesting concerning agranulocytosis.

References

1. Bonkowsky JL, Frazer JK, Buchi KF, Byington CL (2002) Metamizole use by Latino immigrants: a common and potentially harmful home remedy. Pediatrics. 109:e98. doi: 10.1542/peds.109.6.e98
2. Pereira PC, Barraviera B, Marcondes J, Leite CV, Meira DA, Inoue T, Morceli J (1985) Progressive subacute paracoccidioidomycosis. Treatment of a patient with amphotericin B and parenteral feeding]. Revista do Instistuto de Medicina Tropical de Sao Paulo. 27 (5): 268-273. doi: 10.1590/s0036-46651985000500007
3. Sadusk JF (1965) Planning in the Food and drug administration for regulation of prescription drug advertising. Current Therapeutic Research and Clinical Experiments. 18: 332-336. doi: Nil.
4. Levy M, Zylber-Katz E, Rosenkranz B (1995) Clinical pharmacokinetics of dipyrone and its metabolites. Clinical Pharmacokinetics. 28: 216-234. doi: 10.2165/00003088-199528030-00004
5. Vlahov V, Badian M, Verho M, Bacracheva N (1990) Pharmacokinetics of metamizol metabolites in healthy subjects after a single oral dose of metamizol sodium. European Journal of Clinical Pharmacology. 38 (1): 61-65. doi: 10.1007/BF00314805
6. Geisslinger G, Bocker R, Levy M (1996) High-performance liquid chromatographic analysis of dipyrone metabolites to study their formation in human liver microsomes. Pharmacological Research. 13 (8): 1272-1275. doi: 10.1023/a:1016088925786
7. Nelson AC, Huang W, Moody DE (2001) Variables in human liver microsome preparation: impact on the kinetics of l-alpha-acetylmethadol (LAAM) ndemethylation and dextromethorphan O-demethylation. Drug Metabolism and Disposition. 29 (3): 319325. PMID: 11181502.
8. Huskey SW, Dean DC, Miller RR, Rasmusson GH, Chiu SH (1995) Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. Drug Metabolism and Disposition. 23 (10): 1126-1135. PMID: 8654202.
9. Tisi DK, Emard JJ, Koski KG (2004) Total protein concentration in human amniotic fluid is negatively associated with infant birth weight. Journal of Nutrition. 134 (7): 1754-1758. doi: 10.1093/jn/134.7.1754
10. Störmer E, von Moltke LL, Shader RI, Greenblatt DJ (2000) Drug Metabolism and Disposition. 28 (10): 1168-1175. doi: Nil.
11. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI (1994) Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry. 33 (7): 1743-1752. doi: 10.1021/bi00173a017
12. Asmardi G, Jamali F (1983) High-performance liquid chromatography of dipyrone and its active metabolite in biological fluids. Journal of Chromatography. 277: 183-189. doi: 10.1016/s0378-4347(00)84835-5
13. Salsali M, Holt A, Baker GB (2004) Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell and Molecular Neurobiology. 24 (1): 63-76. doi: 10.1023/b:cemn.0000012725.31108.4a
14. Hemeryck A, Belpaire FM (2002) Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Current Drug Metabolism. 3 (1): 13-37. doi: 10.2174/1389200023338017
15. Blaisdell J, Mohrenweiser H, Jackson J, Ferguson S, Coulter S, Chanas B, Xi T, Ghanayem B, Goldstein JA (2002) Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 12: 703-711. doi: 10.1097/00008571-200212000-00004

Citation :

Abdalla SOA (2022) Role of human microsomes in in vitro metabolism of metamizole. Mediterr J Pharm Pharm Sci. 2 (1): 103-108. [Article number: 59]. https://doi.org/10.5281/zenodo.6399950